References
- Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise - was it inevitable? Climacteric 2002;5:317–25
- Lawton BA, Rose SB, Dowell AC. Cessation of the WHI and WISDOM trials: a New Zealand perspective [Comment]. Climacteric 2002;5: 326–8
- Komesaroff PA. A tale of two studies: reflections on WHI and WISDOM [Comment]. Climacteric 2002;5:329–31
- Fiorica JV. Closure of WISDOM and combined HRT arm of WHI [Letter]. Climacteric 2002;5: 402
- Beral V for Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047–59
- Zandi PP, Carlson MC, Plassman BL, et al. for the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. J Am Med Assoc 2002;288: 2123–9
- Zec RF, Trivedi MA. Effects of hormone replace-ment therapy on cognitive aging and dementia risk in postmenopausal women: a review of ongoing large-scale, long-term clinical trials. Climacteric 2002;5:122–34
- Den Tonkelaar I, De Boer EJ, Broekmans FJ, Te Velde ER. Executive summary of the Stagesof Reproductive Aging Workshop (STRAW): not less, but more confusion [Letter]. Climacteric 2002;5:399–401
- MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy use over a decade in an Australian population. Climacteric 2002; 5:351–6
- de Lignieres B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002;5:332–40